SUMMARY
The opioid pandemic highlights the urgent needs to understand pain mechanisms and identify novel,
non-opioid therapeutic targets to treat pain. Ion channels involve in almost all aspects of pain sensation.
Therefore, targeting ion channels has been considered as one of the most promising strategies to replace
opioid analgesics for pain treatment. However, most of ion channels are widely expressed in the nervous
system. Thus, how to specifically target ion channels in pain transmission pathway without affecting their
other critical functions becomes a bottleneck in translating this strategy into clinical applications.
Interestingly, the activities of many ion channels are controlled by their cell-type specific regulatory
proteins. Targeting these regulatory proteins to control ion channels in pain pathways thus presents a
novel and highly specific approach to prevent ion channels-mediated pain with minimal to no side effects.
Our preliminary results showed that Lrrc55, an understudied regulatory subunit of BK potassium channel,
is expressed in a subset of dorsal root ganglion (DRG) neurons and spinal cord lamina i-ii neurons. Our
preliminary data also demonstrated that knockout of Lrrc55 abolishes mechanical pain without affecting
thermal heat pain in an inflammatory pain model and a nerve injury pain model. Our findings suggest that
LRRC55 might be a novel candidate target for treating pain, possibly selective for mechanical pain. In
this high-risk, high-reward application, two investigators will bring complementary and unique expertise
in ion channel biology and pain to: 1) delineate LRRC55’s roles in chronic pain behaviors using the Lrrc55
deficient mice; 2) quantify functional changes of Lrrc55 expression in DRG and spinal cord neurons after
chronic pain; and 3) test if knockdown of Lrrc55 in DRG and spinal cord neurons can be an effective
strategy to suppress chronic pain. Our study will be the first to demonstrate LRRC55’s neurological
function in pain. More importantly, success of this project can open a new avenue to develop novel and
specific therapeutics to target cell-type specific ion channel regulatory proteins to replace opioid-based
pain killers.
Public Health Relevance Statement
Project Narrative:
The epidemic of chronic pain and opioid overdose in the US demands the identification of new and
effective alternative therapies. This high-risk, high-reward application will elucidate the unknown function
of an understudied potassium channel regulatory protein, LRRC55, in pain, and explore if targeting
LRRC55 can be a novel pain management strategy.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
044387793
UEI
TP7EK8DZV6N5
Project Start Date
19-September-2024
Project End Date
31-August-2026
Budget Start Date
19-September-2024
Budget End Date
31-August-2026
Project Funding Information for 2024
Total Funding
$444,125
Direct Costs
$275,000
Indirect Costs
$169,125
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$444,125
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21NS136065-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21NS136065-01
Patents
No Patents information available for 1R21NS136065-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21NS136065-01
Clinical Studies
No Clinical Studies information available for 1R21NS136065-01
News and More
Related News Releases
No news release information available for 1R21NS136065-01
History
No Historical information available for 1R21NS136065-01
Similar Projects
No Similar Projects information available for 1R21NS136065-01